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Summary
Toward our goal of personalized medicine, we comprehensively profiled
pre-treatment malignant plasma cells from multiple myeloma patients and
prospectively identified pathways predictive of favourable response to bort-
ezomib-based treatment regimens. We utilized two complementary quanti-
tative proteomics platforms to identify differentially-regulated proteins
indicative of at least a very good partial response (VGPR) or complete
response/near complete response (CR/nCR) to two treatment regimens
containing either bortezomib, liposomal doxorubicin and dexamethasone
(VDD), or lenalidomide, bortezomib and dexamethasone (RVD). Our
results suggest enrichment of ‘universal response’ pathways that are com-
mon to both treatment regimens and are probable predictors of favourable
response to bortezomib, including a subset of endoplasmic reticulum stress
pathways. The data also implicate pathways unique to each regimen that
may predict sensitivity to DNA-damaging agents, such as mitochondrial
dysfunction, and immunomodulatory drugs, which was associated with
acute phase response signalling. Overall, we identified patterns of tumour
characteristics that may predict response to bortezomib-based regimens
and their components. These results provide a rationale for further
evaluation of the protein profiles identified herein for targeted selection of
anti-myeloma therapy to increase the likelihood of improved treatment
outcome of patients with newly-diagnosed myeloma.
Keywords: multiple myeloma, lenalidomide, bortezomib, proteomics.
The treatment of multiple myeloma (MM) has improved due
to tremendous progress in recent years following the incor-
poration of immunomodulatory drugs, such as thalidomide,
lenalidomide and pomalidomide, and proteasome inhibitors,
including bortezomib and carfilzomib, into treatment strate-
gies (Richardson et al, 2002, 2005; Dimopoulos et al, 2007;
Harousseau et al, 2009; Dytfeld et al, 2011). Recently-intro-
duced combination regimens using these novel agents show
overall response rates of 90–100%, along with improved rates
of very good partial response (VGPR) approaching 80%,
complete and near complete response rates (CR/nCR) near
60% and stringent complete response (sCR) in up to 50% of
patients (Harousseau & Moreau, 2009; Jakubowiak et al,
2012; Khan et al, 2012). With increasing rates of CR, evalua-
tion of minimal residual disease (MRD) with a variety of
techniques is now emerging as an additional measure of
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depth of response (Jakubowiak et al, 2012; Paiva et al, 2012).
A number of studies have shown association between the
depth of response (e.g. achievement of VGPR or CR/nCR to
a given regimen or treatment strategy) and longer progres-
sion-free survival (PFS) and/or overall survival (OS)
(Jakubowiak et al, 2009; Richardson et al, 2010; Khan et al,
2012). More recently, a similar positive association was
reported for achieving MRD-negative status (Pineda-Roman
et al, 2008; Paiva et al, 2012; Martinez-Lopez et al, 2014).
Observed differences in the degree of response to a given
regimen may reflect variations in the biology of subsets of
myeloma, underscoring the well-established heterogeneity of
the disease within and between patients (Pineda-Roman et al,
2008; Harousseau et al, 2009; Cavo et al, 2010; Chanan-Khan
& Giralt, 2010; Bolli et al, 2014; Lohr et al, 2014). In recog-
nition of these differences, individualized approaches to
treatment of subsets of myeloma or risk-adapted therapeutic
strategies based on pre-treatment cytogenetics and/or gene
expression profiling (GEP) have been proposed (Reece et al,
2009; Zhou et al, 2009; Mikhael et al, 2013). While these
strategies address the treatment recommendations for
patients with different risk factors, a truly individualized
approach to myeloma patient therapy based on pre-treat-
ment tumour characteristics that predicts very good response
(e.g. VGPR or CR) and is statistically associated with
improved time-to-event is lacking. Research in recent years
has uncovered key targets and pathways involved in the
response to the most common anti-myeloma agents, includ-
ing cereblon as a target for immunomodulatory drugs (Zhu
et al, 2011; Broyl et al, 2013; Gandhi et al, 2014), and TJP1
and XBP1 as markers of sensitivity to proteasome inhibitors
(Leung-Hagesteijn et al, 2013; Zhang et al, 2013). These dis-
coveries, along with characterization of new or previously
unknown mutations associated with myeloma, such as muta-
tions in BRAF (Chapman et al, 2011; Lohr et al, 2014), pro-
vide the opportunity for marker-based individualized therapy
and for targeted selection of anti-myeloma agents to improve
treatment outcome. However, translation of these discoveries
into clinical practice is still in very early phases and more
research is needed to advance precision medicine in mye-
loma.
Among various efforts to advance personalized therapy,
proteomics-based techniques provide the opportunity to
comprehensively interrogate the molecular heterogeneity of
MM at the proteome level, which may in turn facilitate the
implementation of marker-based individualized therapies
(Unwin et al, 2006; Nicolas et al, 2011). Advanced quanti-
tative proteomic technologies have been applied in studies
of primary patient samples to identify biomarkers of dis-
ease and putative new targets for treatment and also to
assist in the selection of initial therapy (Taguchi et al,
2007; Liang et al, 2012). Quantitative mass-spectrometry
(MS)-based approaches, such as isobaric chemical labelling
[e.g. isobaric tags for relative and absolute quantitation
(iTRAQ)], are capable of accurate, precise and reproducible
quantification and provide deep proteome coverage (Kesh-
amouni et al, 2006). While several proteomic methodologies
have been applied to basic research questions about MM
biology and pathogenesis (reviewed in Cumova et al, 2011),
there remains an unmet need for applying these technolo-
gies to the translation of protein-based biomarker discover-
ies into the clinic and thus improving and/or tailoring
patient care.
In this paper, we present results from proteomic profiling
of naive MM patient plasma cells (PC) to find patterns
indicative of at least VGPR or CR/nCR to two treatment
regimens: VDD (bortezomib, liposomal doxorubicin, dexa-
methasone) and RVD (lenalidomide, bortezomib, dexameth-
asone), respectively. Using complementary platforms of
iTRAQ and label-free (LB) quantitative MS, and also GEP
for VDD patients, we derived signatures associated with
achievement of at least VGPR or CR/nCR to initial treatment
and identified patterns of protein pathways associated with
different levels of response to treatment with these two regi-
mens.
Materials and methods
Myeloma patient samples and plasma cell enrichment
Bone marrow aspirates were obtained from 18 patients trea-
ted on a Phase II clinical trial with VDD (NCT00116961),
and 16 patients enrolled at the University of Michigan site
in the Phase II portion of the multi-site frontline clinical
trial with RVD (NCT00378105). After approval by the site’s
Institutional Review Board, informed consent to treatment
protocols and sample procurement was obtained for all
cases included in this study. Details of both studies are
described elsewhere (Jakubowiak et al, 2009; Richardson
et al, 2010). Plasma cells (PC) from pre-treatment bone
marrow aspirates were enriched by negative selection
(RosetteSep Multiple Myeloma enrichment cocktail, Stem
Cell Technologies, Vancouver, BC, Canada) according to
the manufacturer’s recommendations. Pellets containing
05 9 106 PC were flash frozen for storage. Only samples
containing at least 80% PC purity, which was confirmed by
Wright-Giemsa staining of post-enrichment cytospins, were
further analysed.
Sample preparation for proteomics platforms
Isobaric tags for relative and absolute quantitation (iTRAQ). All
reagents are from the iTRAQ 8-plex kit (Applied Biosystems,
ThermoFisher Scientific, Waltham, MA, USA). Lysates from
PC pellets were prepared according to the manufacturer’s pro-
tocol. Each iTRAQ 8-plex experiment consisted of peptides
from 05 9 106 MM1.S cell lysates labelled with reagents 113
and 121 used as an internal control. Half of the remaining
reagents were used to label samples from patients who
achieved at least VGPR in the VDD portion of the study and
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at least nCR for RVD, and the remaining half were used to
label samples from patients with lesser response. The labelled
peptide mixture was fractionated on a strong cation exchange
(SCX) MicroSpin column with sequential elution of bound
peptides. The eluate was dried and reconstituted in 01%
trifluoroacetic acid (TFA) and then separated by reversed
phase chromatography using a Zorbax 300 SB C18 column.
Column effluent was mixed with matrix-assisted laser
desorption/ionization (MALDI) matrix and spotted onto
192-well MALDI target plates that were later analysed by
tandem MS. The MS and MS/MS spectra were acquired on
an Applied Biosystems 4800 Proteomics Analyser [time-of-
flight (TOF)/TOF; AB SCIEX, Framingham, MA, USA] in
positive ion reflection mode. Single-stage mass spectra for all
samples were collected first and in each sample well MS/MS
spectra were acquired from the 12 most intense peaks above
the signal-to-noise ratio threshold of 60. Protein identifica-
tion and quantification were carried out using PROTEINPILOT
software v2.0.1 (AB SCIEX) and the Celera protein sequence
database (https://www.celera.com/), which comprises
sequences from NCBI Refseq, Swiss-Prot, and TrEMBL data-
bases. For assigning sequence identity, the Paragon algorithm
was used (Shilov et al, 2007). All reported proteins were
identified with a false discovery rate (FDR) <1% as deter-
mined by Paragon. Relative quantification of proteins was
performed on the MS/MS scan using the area under the
peaks at 113, 114, 115, 116, 117, 118, 119 and 121 Da,
which are the masses of the tags corresponding to the
iTRAQ reagents (Keshamouni et al, 2006). The peak areas of
the iTRAQ reporters in each peptide were used to calculate
ratios of patients (labels 114–119) versus the control MM1.S
cell lysates used as reference for further analysis (Keshamo-
uni et al, 2006). The reported ratios were automatically nor-
malized using the applied bias factor obtained from the
median ratio of all proteins that came from all the SCX
fractions that were in each MS/MS run.
Label-free quantitation. Pellets containing 05 9 106 PC
from the same patients that were analysed by iTRAQ were
lysed in radioimmunoprecipitation assay (RIPA) buffer
(Pierce, ThermoFisher Scientific). Denatured samples were
separated on 4–12% Bis-Tris gels (NuPAGE Novex; Invitro-
gen, ThermoFisher Scientific), which were stained with Gel-
Code Blue (ThermoFisher Scientific). After each lane was
cut into 22 equal pieces, gel plugs were de-stained with
30% methanol, washed with 25 mM ammonium bicarbon-
ate in 50% acetonitrile (ACN), reduced with 10 mM dith-
iothreitol (ThermoFisher Scientific), alkylated using 50 mM
iodoacetamide (Fluka Chemie, Sigma Aldrich Corporate, St.
Louis, MO USA) and digested with trypsin (Sigma Aldrich
Corporate). Peptides were extracted first with 01% TFA in
60% ACN and subsequently with 01% TFA in 100% ACN.
Each supernatant was collected, pooled and dried, then
reconstituted in solvent prior to liquid chromatography
(LC)/MS analysis. Samples were analysed via liquid
chromatography-electrospray ionization-tandem mass spec-
trometry (LC-ESI-MS/MS) on a linear ion trap mass spec-
trometer (LTQ; ThermoFisher Scientific) coupled to an
Agilent Technologies (Santa Clara, CA, USA) nano LC sys-
tem and a C18 reversed phase LC column (Micro-Tech Sci-
entific, Orange, CA, USA). Data Dependent Analysis (DDA)
mode was utilized on the LTQ to perform MS on all ions
above an ion count of 1000.
Tandem MS spectra from the LTQ were searched
with SEQUEST (http://fields.scripps.edu/sequest/index.html)
against the human IPI protein database appended with an
equal number of decoy (reversed) protein sequences (for
FDR estimation). The output files were evaluated by PEPTIDE-
PROPHET (peptide-level analysis) and PROTEINPROPHET (protein
inference) available as part of the Trans-Proteomic Pipeline
(Deutsch et al, 2010). Protein identifications were filtered
using the ProteinProphet-computed probability to achieve
the FDR of <1% as estimated using the target-decoy strategy.
Proteins were quantified using LF spectral counting strategy
using ABACUS (Fermin et al, 2011).
Analysis of protein quantitation data
Proteomic signatures differentiating ≥VGPR from <VGPR for
VDD and CR/nCR from <nCR for the RVD group were cre-
ated from iTRAQ data as follows. First, the data was filtered
by including only those proteins with acceptable control
ratios (i.e. internal control MM1.S lysates with label
113:121 ≤ 15-fold change). Then, for each protein, the
iTRAQ reporter ratios were averaged across patients in both
responder and non-responder groups. The responder to non-
responder expression ratios (i.e. (≥VGPR to <VGPR for
VDD; CR/nCR to <nCR for RVD) were calculated in each of
the three replicate datasets. Finally, these expression ratios
for each protein were averaged across all replicates, which we
denoted as the average protein expression ratio. The cut-off
for differential expression was set at 15-fold, which is often
used in proteomic studies (Ting et al, 2009). Figures S1 and
S2 depicts the distribution of average ratios for proteins
identified in VDD and RVD respectively, with line demarca-
tions indicating proteins significant to responders in each
treatment. Within the responder and non-responder groups,
protein spectral counts were normalized by the total spectral
count and averaged across patients. Protein fold change
between responders and non-responders were calculated
using these spectra counts and then were modelled as a
Gaussian distribution. Figures S3 and S4 depicts the log-scale
distribution of protein fold change in expression between
responders and non-responders for VDD and RVD treatment
regimen. Proteins on either side of a 2-standard deviation
cut-off were selected as being significant to responders of
VDD and RVD treatment. Figures S5 and S6 demonstrate
the efficacy of data processing by comparing protein expres-
sion between LF and iTRAQ analysis for VDD and RVD,
respectively.
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RNA isolation and gene expression profiling (GEP)
Using Qiagen RNeasy minicolumns (Qiagen, Santa Clarita,
CA, USA), total RNA was extracted from the PC of 18 patients
enrolled in the VDD study. RNA quality was determined by
assessing the presence of rRNA bands on an Agilent Bioanaly-
ser (Agilent Technologies). When required, amplification of
the transcriptome was performed using Ovation (Nugen Inc.,
San Carlos, CA, USA) to generate cDNA. cRNA was synthe-
sized according to Affymetrix (Santa Clara, CA, USA) proto-
cols and was labelled and hybridized to the U133plus 20
GeneChip, according to manufacturer’s guidelines. The quality
of the microarray data was analysed using a density plot of all
perfect-match probes for each chip and degradation plot of the
mean intensity for probes ordered according to where they
bind to the mRNA transcript. A t-test was performed to iden-
tify 166 genes that were significantly different between ≥VGPR
and <VGPR groups (P < 0001). Through permutation
analysis using sample labels, an expected FDR of 24% was
determined, and supported using Benjamini–Hochberg
adjusted P-values. Log-rank tests for univariate association
with VGPR were performed to generate heat map column
dendrograms with hierarchical clustering.
Pathway analysis
Identified proteins were mapped to their corresponding gene
symbols. Differentially expressed proteins in both LF and
iTRAQ experimental groups are indicated by +1/1 labels
based on whether they were up- or down-regulated, with 0
label indicating proteins whose expression were unchanged
between analysed groups. Within RVD and VDD, the iTRAQ
and LF lists were combined as follows: Proteins with consistent
labels in both lists were retained. Additionally, proteins with
differential label (+1/1) in one list but with a 0 or missing
label in the other list were retained. Proteins with inconsistent
labels (i.e. +1 in one list, 1 in the other) were ignored.
Signature proteins (i.e. mapped gene symbols) and their labels
were used as input to the Ingenuity Pathway Analysis software
(IPA; Qiagen). Ingenuity Pathway Analysis encompasses the
Ingenuity Pathway Analysis Knowledge Base (IPA KB,
http://www.ingenuity.com/), a hand-curated database of all
published protein interactions. Here, a given signature gene list
was mapped to IPA KB with labels being denoted as ‘Other’
within the analysis. Default parameters were used and species
was selected as human. Pathway analysis was conducted sepa-
rately for RVD and VDD groups, following which a compari-
son analysis was made between them. Fisher’s exact test was
used to calculate P-values for determining significance of over-
lap between the proteins in each dataset and the canonical
pathways within IPA KB. Additionally for each analysis, IPA
software was used to generate hypothetical networks from the
list of molecules (called focus genes) and score them based on
log-scale P-values indicative of the probability of including a
gene in a network purely by random chance.
Similarly to proteomics analysis, the 166 differential genes
from the GEP data from VDD patients were labelled as +1/
1, following which the IPA-determined pathways were
compared to corresponding VDD protein signatures.
Results
Proteomic analysis of patients enrolled in VDD study
The clinical characteristics of the 18 patients used in this
analysis (Table I), were generally comparable to all 40
patients treated with VDD in the phase II trial (Jakubowiak
et al, 2009), with the single exception of higher representa-
tion of patients with deletion of chromosome 13 in the
≥VGPR group (data not shown). Response rates and survival,
including survival based on level of response to 6 weeks of
VDD, were previously reported (Jakubowiak et al, 2009; Dyt-
feld et al, 2011). This time point was selected as a surrogate
endpoint for prediction of PFS, regardless of level of
response in later stages of treatment.
A total of 944 proteins were detected from the iTRAQ
experiments, while the LF approach yielded 900 proteins,
with 512 proteins in common between both methods
(Fig 1A, FDR <1%). Among the 356 differentially expressed
proteins detected from iTRAQ analysis, 195 were up-regu-
lated and 161 were down-regulated in samples from patients
achieving ≥VGPR. From the LF analysis, 90 proteins (40 pro-
teins up-regulated and 50 down-regulated in the ≥VGPR
group) were differentially expressed. In LF method, the strict
definition of differential expression in the data (top and bot-
tom 5% after Gaussian fitting) resulted in assigning no
change to most proteins and only a small overlap of
differentially expressed proteins between the two platforms
(not shown), which is in agreement with previous work (Vel-
laichamy et al, 2009).
Table I. Clinical characteristics of patients treated with RVD and
VDD profiled in this analysis.
Clinical characteristic
VDD
(n = 18)
RVD
(n = 16)
Median age, years (range) 57 (44–74) 60 (43–82)
Sex ratio (male/female) 12/6 8/8
Salmon-Durie stage I/II/III 1/5/12 3/4/9
ISS stage1/2/3 5/5/8 7/6/3
Cytogenetics (SR/HR) 11/7 8/8
Best response (CR/nCR/VGPR/PR/
PD)
2/1/7/8/0 4/4/5/3/0
Alive/Dead 14/4 12/4
Not progressed/Progressed 12/6 10/6
RVD, lenalidomide, bortezomib, dexamethasone; VDD, bortezomib,
liposomal doxorubicin, dexamethasone; ISS, International staging
system; SR, standard risk; HR, high risk; CR, complete response;
nCR, near complete response; VGPR, very good partial response; PR,
partial response; PD, progressive disease.
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Proteomic analysis of patients treated with RVD
Analysis was performed on 16 patients (Table I) treated with
the RVD regimen and was based on whether or not patients
achieved CR/nCR after six cycles of RVD, a prognostic indi-
cator of higher significance than VGPR. The response rates
and survival in the RVD trial have been previously reported
(Richardson et al, 2010).
Based on iTRAQ analysis, a total of 669 proteins were
detected (Fig 1B, FDR <1%). Comparison of proteomic altera-
tions in CR/nCR vs. a lesser response in the RVD cohort of
patients revealed the up-regulation of 161 proteins, while 98
proteins showed reduced expression in iTRAQ analysis. The
LF approach yielded 765 proteins (Fig 1B, FDR <1%), of
which 40 proteins were up-regulated, while 31 proteins were
down-regulated in patient samples associated with nCR/CR
response. Similar to the VDD study, the LF approach in RVD
also demonstrated that a majority of proteins remain
unchanged (top and bottom 5% after Gaussian fitting).
Network analysis of differentially expressed proteins in
VDD and RVD
To understand molecular variations between different levels
of response among the two drug regimens, analysis was per-
formed at the pathway level on both cohorts of samples. In
VDD-treated patients, 211 proteins were up-regulated and
195 down-regulated among those that were mapped to the
IPA KB database after merging the iTRAQ and LF protein
lists (with 27 proteins unmapped). The complete list of
mapped and un-mapped proteins (given as gene symbols)
along with assigned labels is given in Table SI. Figure 2A
depicts the top ten canonical pathways (based on the log of
the p-value from Fisher’s exact test) identified in the cohort
of patients achieving at least VGPR on the VDD regimen, of
which mitochondrial dysfunction (P-value: 144-09), oxidative
phosphorylation (P-value: 200-08), and EIF2 signalling
(P-value: 23708) are most confidently associated. Networks
of proteins with overlaying canonical pathways were gener-
ated for the VDD proteomic profile, and the one with the
highest score (46) had 32 network-seeding focus molecules
and was most closely associated with cell death and survival
(IPA reported P-value: 34007, Figure S7).
In RVD-treated patients, 316 differential proteins were
identified from merging iTRAQ and LF protein lists, of
which 292 were successfully mapped to the IPA KB. Out of
this set, 178 proteins were up-regulated and 114 proteins
were down-regulated in the nCR/CR group (Table SII). As in
the VDD-treated patients, EIF2 signalling is among the top
canonical pathways (P-value: 31712) enriched by proteins
from the signature differentiating patients who achieved at
least nCR in response to RVD (Fig 2B). Other high-scoring
networks include liver X receptor/retinoid X receptor (LXR/
RXR) activation (P-value: 21707) and remodelling of epi-
thelial adherens junctions (P-value: 21907). The IPA-gener-
ated network with the highest score (48) had 31 focus
molecules and was associated most closely with RNA post-
transcriptional modification (P-value = 19508, Figure S8).
Also shown in Figure S2 is the overlap of this network with
the four major canonical pathways identified in Fig 2B.
Using the IPA comparative analysis mode, a comparison of
pathways generated from VDD responders (≥VGPR) was made
with those identified in RVD responders (CR/nCR. Figure 3A
depicts the top common and unique pathways between
cohorts. As shown earlier, differential EIF2 signalling was
found in common and with high confidence scores in both
VDD and RVD. Other high-scoring common differential path-
ways include remodelling of epithelial adherens junctions,
clathrin-mediated endocytosis signalling, epithelial adherens
junction signalling and actin cytoskeleton signalling. Among
the differential pathways, mitochondrial dysfunction was
found to be significant in VDD (P < 005) in contrast with
RVD. Figure 3B shows the oxidative phosphorylation pathway,
a subset of mitochondrial dysfunction, for both VDD and
RVD signature proteins. As can be seen, the presence of
NADH dehydrogenase class of proteins in the VDD signature
profile results in a higher enrichment of this pathway in the
VDD cohort.
GEP of patients treated with VDD
A subset of 24 patients treated with VDD with available
RNA from isolated PC was analysed for GEP using the
iTRAQ Label free
VDD
432 512 388
(A)
iTRAQ Label free
RVD
327 342 423
(B)
Fig 1. Proteomic analysis of samples from VDD (A) and RVD (B)
cohorts. Protein IDs were mapped to gene symbols and tabulated.
(A) Comparison of protein identification using both LF and iTRAQ
on all VDD samples based on achieving at least very good partial
response (VGPR) or better vs. less than VGPR. (B) Comparison of
protein identification using both LF and iTRAQ on all RVD samples
based on achieving near-complete response/complete response (CR)
versus less than CR. RVD, lenalidomide, bortezomib, dexamethasone;
VDD, bortezomib, liposomal doxorubicin, dexamethasone; LF,
Label-free quantitation; iTRAQ, isobaric tags for relative and abso-
lute quantitation
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Affymetrix U133plus 20 GeneChip. Twenty of these samples
passed RNA quality control and 18 samples were evaluable
after GEP analysis, nine from patients achieving ≥VGPR and
nine from patients achieving <VGPR. Of this group, eight
patients were among those subjected to proteomic analysis.
The GEP signature demonstrated 166 genes differentially reg-
ulated in patients based on whether or not VGPR was
achieved in response to VDD therapy (Fig 4). The top 20
differentially up- and down-regulated genes in VDD ≥VGPR
responders are highlighted. Ingenuity Pathway Analysis of
our GEP signature identified oxidative phosphorylation as
the predominant pathway enriched among responders. In
comparison with the VDD GEP data, it was noted that the
COX class of proteins that form Complex IV is up-regulated
at the genome level, but down-regulated at the proteome
level (Fig 5).
Discussion
With recognition of the heterogeneity of MM, there is an
increasing interest in improving treatment using individual-
ized therapy based on pre-treatment disease characteristics
and/or biomarkers. In this report, we describe the novel
application of two independent proteomic techniques to
identify pre-treatment expression patterns in malignant PC
indicative of response to initial treatment with VDD and
RVD. We and others have reported that depth of response
may serve as a surrogate for final endpoints, including PFS
and OS (Dytfeld et al, 2011). Therefore, we used early
response criteria, i.e. achievement of VGPR or CR within six
cycles of treatment, as a predictor of clinical outcome.
The use of multiple proteomic platforms can greatly
expand the sensitivity of observed differences in protein
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(B)Fig 2. Proteomic profiling of differential pro-
teins in VDD and RVD studies. (A) A list of
the top ten canonical pathways identified to be
dominant from the Ingenuity Pathway Analysis
(IPA) of differential proteins indicative of
favourable response to VDD. The threshold is
marked for a P-value of 005. Mitochondrial
dysfunction, oxidative phosphorylation and
EIF2 signalling are identified with most confi-
dence. (B) A list of top ten canonical pathways
identified to be dominant from the IPA analy-
sis of differential proteins identified in the
cohort of RVD patients who achieved near-
complete response/complete response. Thresh-
old is marked for P-value of 005. EIF2 signal-
ling, LXR/RXR activation, remodelling of
epithelial adherens junctions, and acute phase
response signalling were identified with most
confidence. RVD, lenalidomide, bortezomib,
dexamethasone; VDD, bortezomib, liposomal
doxorubicin, dexamethasone.
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expression and improve the probability of establishing a
proteomic signature of response to treatment. Through a
combined analysis of PC samples on iTRAQ and LF plat-
forms, we identified 406 proteins in VDD patients who
achieved at least VGPR versus those with lower response,
and 292 proteins differentiating patients who achieved at
least nCR versus those with lower response to RVD treat-
ment. Although comparative proteomics is a powerful ana-
lytical method for learning the biology of the cell,
considerable issues remain, such as incomplete proteome
coverage and variations in quantitation values for specific
proteins both within and across different platform MS runs.
In addition, we applied stringent statistical analyses in the
LF method by including only the top and bottom 5% of all
identified differentially expressed proteins after Gaussian fit-
ting. This resulted in only modest overlap of identified pro-
teins between LF and iTRAQ (38% in the VDD study and
31% in the RVD). This is comparable to similar published
data (Usaite et al, 2008; Patel et al, 2009), and is a widely
recognized limitation of proteomic methods (Chandramouli
& Qian, 2009; Wang et al, 2012). An optimal approach to
comprehensive analysis has not yet been established and
studies comparing different quantitative proteomics plat-
forms are lacking. We approached the limitations in identi-
fication of a consensus list of differentially expressed
proteins by performing pathway analyses and comparing the
profiles of PC from patients treated with RVD and VDD
based on response. This approach allowed us to consider
groups of proteins rather than individual proteins alone to
predict response and identify statistical differences in pat-
terns associated with response to two treatment regimens,
despite a relatively small number of samples available for
analysis.
Pathway analysis of proteomic profiles of responders to
both RVD and VDD therapy depicted a number of pathways
not only specific to each drug regimen but also in common to
both. For example, our study highlighted the endoplasmic
reticulum (ER) stress response, more specifically EIF2 signal-
ling, as the most prominent pathway associated with patients
that responded best to both regimens (i.e. ≥VGPR on VDD or
CR/nCR on RVD). Because MM PC produce large amounts of
immunoglobulins, they operate with an elevated demand on
the ER and are known to exhibit constitutive activation of ER
stress pathways (Obeng et al, 2006), which function to halt
most protein translation, increase expression of ER chaperones
and, under conditions of extreme or prolonged stress, induce
apoptotic effectors. Interestingly, it is this very nature of MM
PC that renders them more susceptible to proteasome inhibi-
tion, which induces extreme stress in the ER and promotes
apoptosis. Both drug regimens under examination in our
multi-platform proteomic profiling of MM PC contain the
proteasome inhibitor bortezomib. Our data suggest that,
although MM PC require basal ER stress for optimal survival
in the setting of increased metabolic demands, a threshold of
ER stress response-associated proteins may need to be crossed
in order to exhibit an optimal response to proteasome inhibi-
tor-based regimens. Indeed, it has been reported that the
degree of EIF2 phosphorylation itself, a key determinant in the
outcome of ER stress, may be responsible for resistance to
bortezomib (Schewe & Aguirre-Ghiso, 2009), suggesting that,
in patients who did not respond well in our completed trials
(i.e. <VGPR on VDD or <nCR), ER stress responses are some-
how attenuated. In addition, the EIF2 pathway was recently
highlighted as a critical determinant of dexamethasone-
induced apoptosis in MM cells (Burwick et al, 2013). Taken
together, our results suggest that detection of enriched EIF2
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Fig 3. Comparison of pathways between VDD and RVD. (A) EIF2 signalling, LXR/RXR activation, remodelling of epithelial adherens junctions,
clathrin-mediated endocytosis, and actin cytoskeleton signalling are pathways common to both RVD and VDD. Mitochondrial dysfunction was
significantly more prevalent in VDD than RVD. On the other hand, Acute Phase Response signalling and was more prevalent in RVD. (B) Red
depicts up-regulated and green depicts down-regulated. In VDD, Complex-I (NADH Dehydrogenase) is seen to be active along with a down-reg-
ulation of cytochrome c. RVD, lenalidomide, bortezomib, dexamethasone; VDD, bortezomib, liposomal doxorubicin, dexamethasone.
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Predicting Response in Pre-Treatment Myeloma Patient Cells
ª 2015 John Wiley & Sons Ltd 73
British Journal of Haematology, 2015, 170, 66–79
<VGPR ≥VGPR
SYNJ1
RHEBL1
236935_at
RBAK
ALAS1
LOC348180
ZBTB40
C2orf3
ARGHEF9
237060_at
LOC728537
238477_at
IDNK
217604_at
CREM
HEXIM2
SLC41A3
NFX1
PHKA1
WDR42A
FBXL3
TP53BP1
237448_at
GLMN
AP1G1
BCL11B
242364_at
LOC283140
KRTAP2-1
NSUN4
SUPT20H
ANKRD10
GBAS
VASH1
UBAC2
HKR1
C13orf31
RBFOX1
LHFP
KSR1
Fig 4. Gene expression profiling on VDD samples. Gene expression profiling correlation with VDD response in terms of achieving at least VGPR.
The top 20 probe sets/genes increased in those achieving VGPR or better are highlighted in green and the top 20 probe sets/genes decreased in
the same group are highlighted in red. VDD, bortezomib, liposomal doxorubicin, dexamethasone; VGPR, very good partial response.
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Fig 5. Comparison of oxidative phosphorylation pathway between GEP and protein signatures in VDD. Oxidative phosphorylation pathway com-
parison of the VDD GEP signature against the differential protein labels in VDD datasets revealed up-regulation of Complex IV (cytochrome c
oxidase) in the GEP dataset as opposed to down-regulation in the proteomics dataset. VDD, bortezomib, liposomal doxorubicin, dexamethasone;
GEP, gene expression profiling.
Predicting Response in Pre-Treatment Myeloma Patient Cells
ª 2015 John Wiley & Sons Ltd 75
British Journal of Haematology, 2015, 170, 66–79
signalling-associated proteins in pre-treatment MM PC may
serve as a useful ‘universal response pathway’ and predictive
marker of positive response in newly-diagnosed MM patients
treated with a regimen that includes bortezomib and dexa-
methasone.
Although EIF2 signalling was associated with those patients
responding well to both RVD and VDD treatment, other path-
ways were found to be uniquely differentially regulated in each
regimen. The proteomic signature predicting achievement of
≥VGPR to initial treatment with VDD revealed mitochondrial
dysfunction as the top-ranked canonical pathway, which was
not differentially expressed according to outcome in the RVD
cohort. Interestingly, a common phenomenon associated with
deregulated cancer cell proliferation is the corresponding alter-
ation in energy metabolism, which is classically viewed as
mitochondrial dysfunction (reviewed in Ward & Thompson,
2012). Furthermore, changes in expression of specific meta-
bolic enzymes have been associated with sensitivity to genotox-
ic stimuli. Indeed, it has been demonstrated that decreased
expression of a NADH dehydrogenase subunit is associated
with resistance to doxorubicin (Wong et al, 2000). Accord-
ingly, patients achieving better response to VDD demonstrate
an enrichment of these proteins. In addition, enhanced pro-
duction of reactive oxygen species (ROS) has also been shown
to sensitize transformed cells to the effects of genotoxic stress
(Benhar et al, 2001). Our results suggest that in MM PC, mod-
ulation of enzymes that can elevate ROS in the setting of
altered mitochondrial function will provide a therapeutic ben-
efit to those patients receiving a DNA-damaging agent, such as
doxorubicin. In patients treated with RVD, a regimen in which
the thalidomide derivative, lenalidomide, is used in combina-
tion with bortezomib and dexamethasone instead of doxorubi-
cin (as in VDD), enrichment of the Acute Phase Response
Signalling pathway is associated with better response. The pre-
dominant cytokine associated with the Acute Phase Response
is IL6, an essential myeloma cell survival factor. The mecha-
nism of action of immunomodulatory drugs, such as lenalido-
mide, is to inhibit production of pro-inflammatory cytokines,
including TNF (also termed TNFa), IL1B, and IL6, and to co-
stimulate T-cells and natural killer cells to elicit tumouricidal
activity (Richardson et al, 2002). It stands to reason that a
group of patients with an enriched signature of Acute Phase
Response cytokines would benefit from a regimen containing
an immune modulating compound, as demonstrated by our
cohort of best responders among patients treated with RVD.
Altogether, our findings highlight dysregulated, therapeuti-
cally-relevant pathways that are of biological significance to
MM. Furthermore, these studies lay the groundwork for the
application of high-resolution quantitative proteomics to per-
sonalizing treatment options for newly-diagnosed MM
patients. However, prospective validation of these techniques
on a larger cohort of patients is required. Indeed, and as men-
tioned above, one potential drawback of our study is the lim-
ited number of samples in our training sets, i.e. the number of
samples derived from patients enrolled in both VDD and RVD
clinical trials, even if we are confident in our findings and in
the stringency of our statistical analyses. With this in mind, we
are currently prospectively collecting patient samples from
additional trials already in progress, including two with bort-
ezomib-based regimens and one with carfilzomib-based regi-
men, with the correlative objectives to perform much needed
validation analyses based on findings from this report.
As GEP is more widely used for analysis of myeloma sam-
ples, we performed an exploratory comparison of the results
between proteomic platforms and GEP on our VDD samples.
The analysis revealed that all but six of the differentially
expressed genes in our 166-gene GEP model were different
from the proteins identified as differentially expressed in our
proteomic signatures (data not shown). Furthermore, using
IPA to compare oxidative phosphorylation, which was the only
pathway subset enriched at both the proteomic and genomic
level in patients achieving VGPR or better on the VDD regi-
men, showed opposite trends. While GEP highlighted up-regu-
lation of complex IV-associated genes, proteomic evaluation of
this subset demonstrated down-regulation. While potentially
worrisome, overall, these results are in line with the well-recog-
nized phenomenon of limited concordance between GEP and
protein levels, and further support efforts made at interrogat-
ing the more biologically-relevant proteome level (De Wit
et al, 2010; Vogel et al, 2010; Schwanhausser et al, 2011). This
is reinforced by the discovery of novel protein pathway bio-
markers, which our results suggest may be relevant as predic-
tors of response to bortezomib-based therapeutic regimens.
However, we recognize that more work is necessary to deter-
mine the applicability of these pathway-based biomarkers as a
tool to bridge the gap between these translational bench-based
observations and deployment in the clinic.
In summary, profiling of patient samples collected prior
to treatment with VDD and RVD showed, as a proof of con-
cept, that it is possible to identify proteomic patterns specific
to response and treatment outcome. We believe that these
results may represent the first proteomic-based step in a
broader effort to establish marker-based personalized
approaches for the selection of treatment in MM. The pre-
dictive capabilities of these patterns, along with applicability
to therapeutic guidance need to be explored further.
Acknowledgements
The authors would like to thank Diane Durecki and Kathryn
McDonnell for their assistance with clinical data collection.
Financial support: This study was supported by grants to
A.S. and A.J.J. from the Multiple Myeloma Research Founda-
tion and the Leukemia and Lymphoma Society. D.D.
received a research grant from Janssen-Cilag.
Author contributions
D.D., M.K., A.I.N., A.S., and A.J.J. designed and performed
the research study; L.N. and P.G.R. contributed essential
76 ª 2015 John Wiley & Sons Ltd
British Journal of Haematology, 2015, 170, 66–79
D. Dytfeld et al
reagents and tools to complete the study; D.D., S.R., M.K.,
A.M., D.M., M.M.A., L.N., J.J., P.G.R., S.V., A.I.N., A.S., and
A.J.J. took part in data acquisition, analysis, and interpreta-
tion; D.D., S.R., M.K., A.M., D.M., M.M.A., J.J., P.G.R., S.V.,
A.I.N., A.S., and A.J.J. wrote, reviewed, and/or revised the
manuscript; D.D., S.R., M.K., A.M., D.M., M.M.A., L.N., J.J.,
P.G.R., S.V., A.I.N., A.S., and A.J.J. approved the final ver-
sion of the manuscript.
Conflict of interest
A.J.J. is a consultant and member of the speakers bureau and
advisory board for Millennium Pharmaceuticals, Inc., Cel-
gene, and Janssen-Cilag, and has received honoraria from
Millennium Pharmaceuticals, Inc., Celgene, Janssen-Cilag,
and Takeda. D.D. has received honoraria from Janssen-Cilag.
The remaining authors declare no competing financial
interests.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Fig S1. Detection of proteins significant to responders in
VDD using iTRAQ.
Fig S2. Detection of proteins significant to responders in
RVD using iTRAQ.
Fig S3. The ratio of normalized spectrum counts from
VDD samples was calculated and then log-transformed.
Fig S4 The ratio of normalized spectrum counts from
RVD samples was calculated and then log-transformed.
Fig S5. Protein expression comparison between LF and
iTRAQ experiment in VDD patient samples.
Fig S6. Protein expression comparison between LF and
iTRAQ experiment in RVD patient samples.
Fig S7. Highest scoring network for VDD signature pro-
teins.
Fig S8. Highest scoring network generated for RVD signa-
ture proteins.
Table SI. Proteins differentially regulated between respon-
ders and non responders to VDD (both iTRAQ and LF) suc-
cessfully mapped to IPA KB.
Table SII. Proteins differentially regulated between
responders and non responders to RVD (both iTRAQ and
LF) successfully mapped to IPA KB.
References
Benhar, M., Dalyot, I., Engelberg, D. & Levitzki, A.
(2001) Enhanced ROS production in oncogeni-
cally transformed cells potentiates c-Jun N-ter-
minal kinase and p38 mitogen-activated protein
kinase activation and sensitization to genotoxic
stress. Molecular and Cellular Biology, 21, 6913–
6926.
Bolli, N., Avet-Loiseau, H., Wedge, D.C., Van Loo,
P., Alexandrov, L.B., Martincorena, I., Dawson,
K.J., Iorio, F., Nik-Zainal, S., Bignell, G.R., Hin-
ton, J.W., Li, Y., Tubio, J.M.C., McLaren, S., O’
Meara, S., Butler, A.P., Teague, J.W., Mudie, L.,
Anderson, E., Rashid, N., Tai, Y-T, Shammas,
M.A., Sperling, A.S., Fulciniti, M., Richardson,
P.G., Parmigiani, G., Magrangeas, F., Minvielle,
S., Moreau, P., Attal, M., Facon, T., Futreal,
P.A., Anderson, K.C., Campbell, P.J. & Munshi,
N.C. (2014). Heterogeneity of genomic evolu-
tion and mutational profiles in multiple mye-
loma. Nature Communications 5, doi:10.1038/
ncomms3997.
Broyl, A., Kuiper, R., van Duin, M., van der Holt,
B., el Jarari, L., Bertsch, U., Zweegman, S., Buijs,
A., Hose, D., Lokhorst, H.M., Goldschmidt, H.,
Sonneveld, P., Hg, D-B & German, G.G. (2013)
High cereblon expression is associated with bet-
ter survival in patients with newly diagnosed
multiple myeloma treated with thalidomide
maintenance. Blood, 121, 624–627.
Burwick, N., Delrow, J.J. & Shimamura, A. (2013)
Translational profiling reveals the eIF2 kinase
pathway as a mediator of dexamethasone
induced apoptosis in multiple myeloma. Blood
(ASH Annual Meeting Abstracts), 122, 3104.
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci,
M.T., Pantani, L., Galli, M., Di Raimondo, F.,
Crippa, C., Zamagni, E., Palumbo, A., Offidani,
M., Corradini, P., Narni, F., Spadano, A., Pesco-
sta, N., Deliliers, G.L., Ledda, A., Cellini, C.,
Caravita, T., Tosi, P. & Baccarani, M. (2010)
Bortezomib with thalidomide plus dexametha-
sone compared with thalidomide plus dexa-
methasone as induction therapy before, and
consolidation therapy after, double autologous
stem-cell transplantation in newly diagnosed
multiple myeloma: a randomised phase 3 study.
Lancet, 376, 2075–2085.
Chanan-Khan, A.A. & Giralt, S. (2010) Importance
of achieving a complete response in multiple
myeloma, and the impact of novel agents. Journal
of Clinical Oncology: Official Journal of the Ameri-
can Society of Clinical Oncology, 28, 2612–2624.
Chandramouli, K, Qian, PY (2009). Proteomics:
challenges, techniques and possibilities to over-
come biological sample complexity. Human Ge-
nomics and Proteomics: HGP, 2009, Dec 8;2009.
pii: 239204. doi: 10.4061/2009/239204
Chapman, M.A., Lawrence, M.S., Keats, J.J., Cibuls-
kis, K., Sougnez, C., Schinzel, A.C., Harview, C.L.,
Brunet, J.-P., Ahmann, G.J., Adli, M., Anderson,
K.C., Ardlie, K.G., Auclair, D., Baker, A., Bergsa-
gel, P.L., Bernstein, B.E., Drier, Y., Fonseca, R.,
Gabriel, S.B., Hofmeister, C.C., Jagannath, S., Ja-
kubowiak, A.J., Krishnan, A., Levy, J., Liefeld, T.,
Lonial, S., Mahan, S., Mfuko, B., Monti, S., Per-
kins, L.M., Onofrio, R., Pugh, T.J., Rajkumar,
S.V., Ramos, A.H., Siegel, D.S., Sivachenko, A.,
Stewart, A.K., Trudel, S., Vij, R., Voet, D., Winc-
kler, W., Zimmerman, T., Carpten, J., Trent, J.,
Hahn, W.C., Garraway, L.A., Meyerson, M.,
Lander, E.S., Getz, G. & Golub, T.R. (2011) Initial
genome sequencing and analysis of multiple mye-
loma. Nature, 471, 467–472.
Cumova, J., Potacova, A., Zdrahal, Z. & Hajek, R.
(2011) Proteomic analysis in multiple myeloma
research. Molecular Biotechnology, 47, 83–93.
De Wit, M., Keil, D., van der Ven, K., Vandamme,
S., Witters, E. & De Coen, W. (2010) An inte-
grated transcriptomic and proteomic approach
characterizing estrogenic and metabolic effects
of 17 alpha-ethinylestradiol in zebrafish (Danio
rerio). General and Comparative Endocrinology,
167, 190–201.
Deutsch, E.W., Mendoza, L., Shteynberg, D., Far-
rah, T., Lam, H., Tasman, N., Sun, Z., Nilsson,
E., Pratt, B., Prazen, B., Eng, J.K., Martin, D.B.,
Nesvizhskii, A.I. & Aebersold, R. (2010) A
guided tour of the Trans-Proteomic Pipeline.
Proteomics, 10, 1150–1159.
Dimopoulos, M., Spencer, A., Attal, M., Prince,
H.M., Harousseau, J.L., Dmoszynska, A., San
Miguel, J., Hellmann, A., Facon, T., Foa, R.,
Corso, A., Masliak, Z., Olesnyckyj, M., Yu,
Z., Patin, J., Zeldis, J.B. & Knight, R.D.
(2007) Lenalidomide plus dexamethasone for
relapsed or refractory multiple myeloma. The
New England Journal of Medicine, 357, 2123–
2132.
Dytfeld, D., Griffith, K.A., Friedman, J., Lebovic,
D., Harvey, C., Kaminski, M.S. & Jakubowiak,
A.J. (2011) Superior overall survival of patients
with myeloma achieving very good partial
response or better to initial treatment with bort-
ezomib, pegylated liposomal doxorubicin, and
dexamethasone, predicted after two cycles by a
free light chain- and M-protein-based model:
ª 2015 John Wiley & Sons Ltd 77
British Journal of Haematology, 2015, 170, 66–79
Predicting Response in Pre-Treatment Myeloma Patient Cells
extended follow-up of a phase II trial. Leukae-
mia & Lymphoma, 52, 1271–1280.
Fermin, D., Basrur, V., Yocum, A.K. & Nesvizhskii,
A.I. (2011) Abacus: a computational tool for
extracting and pre-processing spectral count
data for label-free quantitative proteomic analy-
sis. Proteomics, 11, 1340–1345.
Gandhi, A.K., Mendy, D., Waldman, M., Chen, G.,
Rychak, E., Miller, K., Gaidarova, S., Ren, Y.,
Wang, M., Breider, M., Carmel, G., Mahmoudi,
A., Jackson, P., Abbasian, M., Cathers, B.E.,
Schafer, P.H., Daniel, T.O., Lopez-Girona, A.,
Thakurta, A. & Chopra, R. (2014) Measuring
cereblon as a biomarker of response or resis-
tance to lenalidomide and pomalidomide
requires use of standardized reagents and under-
standing of gene complexity. British Journal of
Haematology, 164, 233–244.
Harousseau, J.L. & Moreau, P. (2009) Autologous
hematopoietic stem-cell transplantation for mul-
tiple myeloma. The New England Journal of
Medicine, 360, 2645–2654.
Harousseau, J.L., Attal, M. & Avet-Loiseau, H.
(2009) The role of complete response in multi-
ple myeloma. Blood, 114, 3139–3146.
Jakubowiak, A.J., Kendall, T., Al-Zoubi, A.,
Khaled, Y., Mineishi, S., Ahmed, A., Campagna-
ro, E., Brozo, C., Braun, T., Talpaz, M. & Ka-
minski, M.S. (2009) Phase II trial of
combination therapy with bortezomib, pegylated
liposomal doxorubicin, and dexamethasone in
patients with newly diagnosed myeloma. Journal
of Clinical Oncology: Official Journal of the Amer-
ican Society of Clinical Oncology, 27, 5015–5022.
Jakubowiak, A.J., Dytfeld, D., Griffith, K.A., Lebo-
vic, D., Vesole, D.H., Jagannath, S., Al-Zoubi,
A., Anderson, T., Nordgren, B., Detweiler-Short,
K., Stockerl-Goldstein, K., Ahmed, A., Jobkar,
T., Durecki, D.E., McDonnell, K., Mietzel, M.,
Couriel, D., Kaminski, M. & Vij, R. (2012) A
phase 1/2 study of carfilzomib in combination
with lenalidomide and low-dose dexamethasone
as a frontline treatment for multiple myeloma.
Blood, 120, 1801–1809.
Keshamouni, V.G., Michailidis, G., Grasso, C.S.,
Anthwal, S., Strahler, J.R., Walker, A., Arenberg,
D.A., Reddy, R.C., Akulapalli, S., Thannickal,
V.J., Standiford, T.J., Andrews, P.C. & Omenn,
G.S. (2006) Differential protein expression pro-
filing by iTRAQ-2DLC-MS/MS of lung cancer
cells undergoing epithelial-mesenchymal transi-
tion reveals a migratory/invasive phenotype.
Journal of Proteome Research, 5, 1143–1154.
Khan, M.L., Reeder, C.B., Kumar, S.K., Lacy,
M.Q., Reece, D.E., Dispenzieri, A., Gertz, M.A.,
Greipp, P., Hayman, S., Zeldenhurst, S., Dingli,
D., Lust, J., Russell, S., Laumann, K.M., Mikh-
ael, J.R., Leif Bergsagel, P., Fonseca, R., Vincent
Rajkumar, S. & Keith Stewart, A. (2012) A
comparison of lenalidomide/dexamethasone
versus cyclophosphamide/lenalidomide/dexa-
methasone versus cyclophosphamide/bortezo-
mib/dexamethasone in newly diagnosed
multiple myeloma. British Journal of Haematol-
ogy, 156, 326–333.
Leung-Hagesteijn, C., Erdmann, N., Cheung, G.,
Keats, J.J., Stewart, A.K., Reece, D.E., Chung,
K.C. & Tiedemann, R.E. (2013) Xbp1s-negative
tumor B cells and pre-plasmablasts mediate
therapeutic proteasome inhibitor resistance in
multiple myeloma. Cancer Cell, 24, 289–304.
Liang, S., Xu, Z., Xu, X., Zhao, X., Huang, C. &
Wei, Y. (2012) Quantitative proteomics for can-
cer biomarker discovery. Combinatorial Chemis-
try High Throughput Screening, 15, 221–231.
Lohr, J.G., Stojanov, P., Carter, S.L., Cruz-Gordil-
lo, P., Lawrence, M.S., Auclair, D., Sougnez, C.,
Knoechel, B., Gould, J., Saksena, G., Cibulskis,
K., McKenna, A., Chapman, M.A., Straussman,
R., Levy, J., Perkins, L.M., Keats, J.J., Schumach-
er, S.E., Rosenberg, M., Multiple Myeloma
Research, C., Getz, G. & Golub, T.R. (2014)
Widespread genetic heterogeneity in multiple
myeloma: implications for targeted therapy.
Cancer Cell, 25, 91–101.
Martinez-Lopez, J., Lahuerta, J.J., Pepin, F., Gonz-
alez, M., Barrio, S., Ayala, R., Puig, N., Montal-
ban, M.A., Paiva, B., Weng, L., Jimenez, C.,
Sopena, M., Moorhead, M., Cedena, T., Rapado,
I., Mateos, M.V., Rosinol, L., Oriol, A., Blan-
chard, M.J., Martinez, R., Blade, J., San Miguel,
J., Faham, M. & Garcia-Sanz, R. (2014) Prog-
nostic value of deep sequencing method for
minimal residual disease detection in multiple
myeloma. Blood, 123, 3073–3079.
Mikhael, J.R., Dingli, D., Roy, V., Reeder, C.B.,
Buadi, F.K., Hayman, S.R., Dispenzieri, A.,
Fonseca, R., Sher, T., Kyle, R.A., Lin, Y., Russell,
S.J., Kumar, S., Bergsagel, P.L., Zeldenrust, S.R.,
Leung, N., Drake, M.T., Kapoor, P., Ansell,
S.M., Witzig, T.E., Lust, J.A., Dalton, R.J., Gertz,
M.A., Stewart, K., Rajkumar, S.V., Chanan-
Khan, A. & Lacy, M.Q. (2013) Management of
newly diagnosed symptomatic multiple mye-
loma: updated Mayo Stratification of Myeloma
and Risk-Adapted Therapy (mSMART) consen-
sus guidelines 2013. Mayo Clinic Proceedings, 88,
360–376.
Nicolas, E., Ramus, C., Berthier, S., Arlotto, M.,
Bouamrani, A., Lefebvre, C., Morel, F., Garin, J.,
Ifrah, N., Berger, F., Cahn, J.Y. & Mossuz, P.
(2011) Expression of S100A8 in leukemic cells
predicts poor survival in de novo AML patients.
Leukemia, 25, 57–65.
Obeng, E.A., Carlson, L.M., Gutman, D.M., Har-
rington, W.J. Jr, Lee, K.P. & Boise, L.H. (2006)
Proteasome inhibitors induce a terminal
unfolded protein response in multiple myeloma
cells. Blood, 107, 4907–4916.
Paiva, B., Gutierrez, N.C., Rosinol, L., Vidriales,
M.B., Montalban, M.A., Martinez-Lopez, J.,
Mateos, M.V., Cibeira, M.T., Cordon, L., Oriol,
A., Terol, M.J., Echeveste, M.A., de Paz, R., de
Arriba, F., Palomera, L., de la Rubia, J., Diaz-
Mediavilla, J., Sureda, A., Gorosquieta, A., Al-
egre, A., Martin, A., Hernandez, M.T., Lahuerta,
J.J., Blade, J. & San Miguel, J.F. (2012) High-risk
cytogenetics and persistent minimal residual dis-
ease by multiparameter flow cytometry predict
unsustained complete response after autologous
stem cell transplantation in multiple myeloma.
Blood, 119, 687–691.
Patel, V.J., Thalassinos, K., Slade, S.E., Connolly,
J.B., Crombie, A., Murrell, J.C. & Scrivens, J.H.
(2009) A comparison of labeling and label-free
mass spectrometry-based proteomics
approaches. Journal of Proteome Research, 8,
3752–3759.
Pineda-Roman, M., Zangari, M., Haessler, J.,
Anaissie, E., Tricot, G., van Rhee, F., Crowley,
J., Shaughnessy, J.D. Jr & Barlogie, B. (2008)
Sustained complete remissions in multiple mye-
loma linked to bortezomib in total therapy 3:
comparison with total therapy 2. British Journal
of Haematology, 140, 625–634.
Reece, D., Song, K.W., Fu, T., Roland, B., Chang,
H., Horsman, D.E., Mansoor, A., Chen, C.,
Masih-Khan, E., Trieu, Y., Bruyere, H., Stewart,
D.A. & Bahlis, N.J. (2009) Influence of cytoge-
netics in patients with relapsed or refractory
multiple myeloma treated with lenalidomide
plus dexamethasone: adverse effect of deletion
17p13. Blood, 114, 522–525.
Richardson, P.G., Schlossman, R.L., Weller, E.,
Hideshima, T., Mitsiades, C., Davies, F., Le-
Blanc, R., Catley, L.P., Doss, D., Kelly, K.,
McKenney, M., Mechlowicz, J., Freeman, A.,
Deocampo, R., Rich, R., Ryoo, J.J., Chauhan,
D., Balinski, K., Zeldis, J. & Anderson, K.C.
(2002) Immunomodulatory drug CC-5013 over-
comes drug resistance and is well tolerated in
patients with relapsed multiple myeloma. Blood,
100, 3063–3067.
Richardson, P.G., Sonneveld, P., Schuster, M.W.,
Irwin, D., Stadtmauer, E.A., Facon, T., Harous-
seau, J.L., Ben-Yehuda, D., Lonial, S., Goldsch-
midt, H., Reece, D., San-Miguel, J.F., Blade, J.,
Boccadoro, M., Cavenagh, J., Dalton, W.S.,
Boral, A.L., Esseltine, D.L., Porter, J.B., Schenk-
ein, D. & Anderson, K.C. Assessment of Protea-
some Inhibition for Extending Remissions I
(2005). Bortezomib or high-dose dexamethasone
for relapsed multiple myeloma. The New Eng-
land Journal of Medicine 352: 2487–2498.
Richardson, P.G., Weller, E., Lonial, S., Ja-
kubowiak, A.J., Jagannath, S., Raje, N.S., Avigan,
D.E., Xie, W., Ghobrial, I.M., Schlossman, R.L.,
Mazumder, A., Munshi, N.C., Vesole, D.H.,
Joyce, R., Kaufman, J.L., Doss, D., Warren, D.L.,
Lunde, L.E., Kaster, S., Delaney, C., Hideshima,
T., Mitsiades, C.S., Knight, R., Esseltine, D.L. &
Anderson, K.C. (2010) Lenalidomide, bortezo-
mib, and dexamethasone combination therapy
in patients with newly diagnosed multiple mye-
loma. Blood, 116, 679–686.
Schewe, D.M. & Aguirre-Ghiso, J.A. (2009) Inhibi-
tion of eIF2alpha dephosphorylation maximizes
bortezomib efficiency and eliminates quiescent
multiple myeloma cells surviving proteasome
inhibitor therapy. Cancer Research, 69, 1545–
1552.
Schwanhausser, B., Busse, D., Li, N., Dittmar, G.,
Schuchhardt, J., Wolf, J., Chen, W. & Selbach,
M. (2011) Global quantification of mammalian
gene expression control. Nature, 473, 337–342.
78 ª 2015 John Wiley & Sons Ltd
British Journal of Haematology, 2015, 170, 66–79
D. Dytfeld et al
Shilov, I.V., Seymour, S.L., Patel, A.A., Loboda, A.,
Tang, W.H., Keating, S.P., Hunter, C.L., Nuway-
sir, L.M. & Schaeffer, D.A. (2007) The Paragon
Algorithm, a next generation search engine that
uses sequence temperature values and feature
probabilities to identify peptides from tandem
mass spectra. Molecular & Cellular Proteomics:
MCP, 6, 1638–1655.
Taguchi, F., Solomon, B., Gregorc, V., Roder, H.,
Gray, R., Kasahara, K., Nishio, M., Brahmer, J.,
Spreafico, A., Ludovini, V., Massion, P.P.,
Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsy-
pin, M., Hunsucker, S.W., Caprioli, R., Duncan,
M.W., Hirsch, F.R., Bunn, P.A. Jr & Carbone,
D.P. (2007) Mass spectrometry to classify non-
small-cell lung cancer patients for clinical out-
come after treatment with epidermal growth fac-
tor receptor tyrosine kinase inhibitors: a
multicohort cross-institutional study. Journal of
the National Cancer Institute, 99, 838–846.
Ting, L., Cowley, M.J., Hoon, S.L., Guilhaus, M.,
Raftery, M.J. & Cavicchioli, R. (2009) Normali-
zation and statistical analysis of quantitative
proteomics data generated by metabolic labeling.
Molecular & Cellular Proteomics: MCP, 8, 2227–
2242.
Unwin, R.D., Smith, D.L., Blinco, D., Wilson, C.L.,
Miller, C.J., Evans, C.A., Jaworska, E., Baldwin,
S.A., Barnes, K., Pierce, A., Spooncer, E. &
Whetton, A.D. (2006) Quantitative proteomics
reveals posttranslational control as a regulatory
factor in primary hematopoietic stem cells.
Blood, 107, 4687–4694.
Usaite, R., Wohlschlegel, J., Venable, J.D., Park,
S.K., Nielsen, J., Olsson, L. & Yates Iii, J.R. (2008)
Characterization of global yeast quantitative pro-
teome data generated from the wild-type and glu-
cose repression saccharomyces cerevisiae strains:
the comparison of two quantitative methods.
Journal of Proteome Research, 7, 266–275.
Vellaichamy, A., Sreekumar, A., Strahler, J.R., Raj-
endiran, T., Yu, J., Varambally, S., Li, Y.,
Omenn, G.S., Chinnaiyan, A.M. & Nesvizhskii,
A.I. (2009) Proteomic interrogation of androgen
action in prostate cancer cells reveals roles of
aminoacyl tRNA synthetases. PLoS ONE, 4,
e7075.
Vogel, C., Abreu Rde, S., Ko, D., Le, S.Y., Shapiro,
B.A., Burns, S.C., Sandhu, D., Boutz, D.R., Mar-
cotte, E.M. & Penalva, L.O. (2010) Sequence sig-
natures and mRNA concentration can explain
two-thirds of protein abundance variation in a
human cell line. Molecular Systems Biology, 6,
400.
Wang, H., Alvarez, S. & Hicks, L.M. (2012) Com-
prehensive comparison of iTRAQ and label-free
LC-based quantitative proteomics approaches
using two Chlamydomonas reinhardtii strains of
interest for biofuels engineering. Journal of Pro-
teome Research, 11, 487–501.
Ward, P.S. & Thompson, C.B. (2012) Metabolic
reprogramming: a cancer hallmark even war-
burg did not anticipate. Cancer Cell, 21, 297–
308.
Wong, T.W., Yu, H.Y., Kong, S.K., Fung, K.P. &
Kwok, T.T. (2000) The decrease of mitochon-
drial NADH dehydrogenease and drug induced
apoptosis in doxorubicin resistant A431 cells.
Life Sciences, 67, 1111–1118.
Zhang, X.-D., Baladandayuthapani, V., Lin, H.Y.,
Barlogie, B., Usmani, S.Z., Yang, L. & Orlowski,
R.Z. (2013) Identification of Tight Junction Pro-
tein (TJP)-1 As a modulator and biomarker of
proteasome inhibitor sensitivity in multiple
myeloma. Blood (ASH Annual Meeting
Abstracts), 122, 123.
Zhou, Y., Barlogie, B. & Shaughnessy, J.D. Jr
(2009) The molecular characterization and clini-
cal management of multiple myeloma in the
post-genome era. Leukemia, 23, 1941–1956.
Zhu, Y.X., Braggio, E., Shi, C.X., Bruins, L.A.,
Schmidt, J.E., Van Wier, S., Chang, X.B., Bjorkl-
und, C.C., Fonseca, R., Bergsagel, P.L., Orlowski,
R.Z. & Stewart, A.K. (2011) Cereblon expression
is required for the antimyeloma activity of lena-
lidomide and pomalidomide. Blood, 118, 4771–
4779.
ª 2015 John Wiley & Sons Ltd 79
British Journal of Haematology, 2015, 170, 66–79
Predicting Response in Pre-Treatment Myeloma Patient Cells
